Scientific Sessions 2025  /  Diabetes, CKD and CVD Risk: From Mechanisms to Management  /  Mechanisms underlying Diabetic Kidney Disease and CVD Risk
Logo

American Heart Association

  47
  0

Final ID:

Mechanisms underlying Diabetic Kidney Disease and CVD Risk

  • Tuttle, Katherine  ( PROVIDENCE MEDICAL RESEARCH CENTER , Spokane , Washington , United States )
  • Pratley, Richard  ( AdventHealth Orlando , Orlando , Florida , United States )
    • Author Disclosures:
    Katherine Tuttle: DO have relevant financial relationships ; Consultant:Novo Nordisk:Active (exists now) ; Speaker:Boehringer Ingelheim:Active (exists now) ; Speaker:Bayer:Past (completed) ; Speaker:Novo Nordisk:Active (exists now) ; Independent Contractor:Astra Zeneca:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Past (completed) ; Research Funding (PI or named investigator):Travere:Past (completed) ; Consultant:ProKidney:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Lilly:Active (exists now) | Richard Pratley: DO have relevant financial relationships ; Consultant:Abbott Laboratories; Gasherbrum Bio Inc.; Genprex; Getz Pharma:Active (exists now) ; Consultant:Verdiva Bio Dev Limited:Active (exists now) ; Speaker:Lilly USA LLC; Merck; Novo Nordisk:Active (exists now) ; Consultant:Lilly USA LLC; Novo Nordisk; RegeneronPfizer:Active (exists now) ; Research Funding (PI or named investigator):Endogenex Inc.; Sanofi:Active (exists now) ; Consultant:Corcept Therapeutics Incorporated; Rivus Pharmaceuticals Inc.:Active (exists now) ; Research Funding (PI or named investigator):Carmot Therapeutics; Fractyl; Metavention; Novo-Nordisk:Active (exists now) ; Consultant:Boehringer Ingelheim Pharmaceuticals Inc.:Active (exists now) ; Research Funding (PI or named investigator):Biomea Fusion; Dompe; Eli Lilly and Company:Active (exists now) ; Consultant:Bayer Healthcare Pharmaceuticals Inc.; Scholar Rock Inc.:Active (exists now) ; Consultant:Bayer AG; Endogenex Inc.; Hanmi Pharmaceutical Co.; Lexicon Pharmaceuticals:Active (exists now) ; Consultant:AstraZeneca Pharmaceuticals LP:Active (exists now) ; Consultant:Amgen Inc.; F. Hoffman-La Roche Ltd.:Active (exists now) ; Individual Stocks/Stock Options:Altanine Inc.:Active (exists now) ; Consultant:AbbVie Inc.; Eli Lilly and Company; Sun Pharmaceutical Industries:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Diabetes, CKD and CVD Risk: From Mechanisms to Management

Saturday, 11/08/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Case Presentation

Lo Kevin Bryan

The Expanding Therapeutic Options for Diabetic Kidney Disease: A Clinical Trial Overview

Neuen Brendon, Agarwal Rajiv, Rangaswami Janani

More abstracts from these authors:
Panel Discussion

Tuttle Katherine

Going with the FLOW: Understanding the renal effects of GLP-1RA therapy

Tuttle Katherine, Rangaswami Janani

You have to be authorized to contact abstract author. Please, Login
Not Available